EMA Recommends Granting a Marketing Authorisation for Tarlatamab By Ogkologos - April 17, 2026 231 0 Facebook Twitter Google+ Pinterest WhatsApp It is indicated for the treatment of adult patients with extensive-stage SCLC Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Responding to Coronavirus, Cancer Researchers Reimagine Clinical Trials June 29, 2020 Will Ponsegromab Be a Game Changer for Cancer Cachexia? October 17, 2024 Atlantic rowing trio smash world record and raise thousands for cancer... January 24, 2022 Mutational Patterns Drive Metastatic Aggressiveness of Appendiceal Adenocarcinomas December 21, 2022 Load more HOT NEWS FDA Grants Accelerated Approval to Tafasitamab-cxix for DLBCL How we are working with industry to translate research into real... Addressing Racial Disparities in Cancer Care: “Your Stories” Podcast Investment Needed to Bring Down Pancreatic Cancer Death Rates in Europe....
